NASDAQ$ATAI
AtaiBeckley Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Atai reported positive Phase 1b results for VLS-01 and announced clinical development plans for EMP-01, with cash runway extended into 2026.
Atai Life Sciences reported its Q2 2024 financial results, highlighting advancements in its pipeline with positive Phase 1b results for VLS-01 and progress in EMP-01 clinical development. The company's cash, marketable securities, and committed term loan funding are expected to fund operations into 2026. R&D expenses decreased compared to the same period last year, while G&A expenses also saw a reduction. Net loss attributable to stockholders was $57.3 million, compared to $33.0 million for the same period in 2023.
- atai reported positive Phase 1b results for VLS-01 (buccal film DMT) and expects to initiate a Phase 2 study in treatment-resistant depression patients around year-end 2024.
- The company announced clinical development plans for EMP-01 (oral R-MDMA) and anticipates initiating a Phase 2 study in social anxiety disorder patients around year-end 2024.
- atai's cash, marketable securities, and committed term loan funding are expected to fund operations into 2026.
- Net loss attributable to stockholders for the quarter was $57.3 million.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$273K
Forward guidance
atai anticipates several R&D catalysts in the near term, including the initiation of Phase 2 studies for VLS-01 in TRD and EMP-01 in SAD around year-end 2024, as well as topline data readouts for other programs in H2 2024 and 2025.
Tailwinds
- Initiation of VLS-01 Phase 2 study in TRD around year-end 2024.
- Initiation of EMP-01 Phase 2 study in SAD around year-end 2024.
- Initiation of IBX-210 Phase 1b/2a study in opioid use disorder.
- Completion of patient enrollment for BPL-003 Phase 2b study in TRD.
- Topline open-label data for BPL-003 Phase 2a study in alcohol use disorder.
Headwinds
- Potential delays or setbacks in clinical trials.
- Uncertainties in regulatory approvals.
- Risks associated with drug development and commercialization.
- Dependence on third-party collaborations and partnerships.
- Market competition and changing industry dynamics.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro